Sanofi, Regeneron Gets EU OK for Expanded Dupixent Use
30 October 2019 - 12:12AM
Dow Jones News
By Colin Kellaher
Sanofi S.A. (SAN.FR) and Regeneron Pharmaceuticals Inc. (REGN)
on Tuesday said the European Commission approved expanded use of
Dupixent for adults with chronic rhinosinusitis with nasal
polyposis, or CRSwNP.
The companies said Dupixent is now indicated as an add-on
therapy with intranasal corticosteroids for the treatment of adults
with severe CRSwNP for whom therapy with systemic corticosteroids
and/or surgery don't provide adequate disease control.
Sanofi and Regeneron said Dupixent is the first biologic
approved in the European Union for adults with severe CRSwNP, a
disease of the upper airway that obstructs the sinuses and nasal
passages.
Regeneron, of Tarrytown, N.Y., created Dupixent and markets it
jointly in the U.S. with France's Sanofi under a 2007 collaboration
agreement. Sanofi markets the product internationally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 29, 2019 08:57 ET (12:57 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024